Evidence map›Paper›PMID 41773217›Full record

ArticleHealth science reports2026

The Current Landscape and Future Prospects of Vaccine Manufacturing in Africa: Challenges, Innovations, and Opportunities: A Narrative Review.

Courage Chandipwisa, Agness Shimilimo, Olivier Uwishema, Helen Onyeaka

Abstract read
In one paragraph

Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Courage ChandipwisaDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.
Agness ShimilimoReproductive Health Pan African University Life and Earth Sciences (including Health and Agriculture) Ibadan Nigeria.
Olivier UwishemaDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.ORCID https://orcid.org/0000-0002-0692-9027
Helen OnyeakaUniversity of Birmingham. school of Chemical Engineering Birmingham UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Africa has significant challenges in meeting its vaccination needs, including inadequate manufacturing capacity, infrastructure deficiencies, a scarcity of experienced personnel, regulatory hurdles, restricted access to technology and intellectual property. This review evaluates African vaccine manufacturing capacity, region-specific limitations, and highlights significant innovations and policy alternatives to promote vaccine autonomy and equitable public health results. Methods: A comprehensive narrative evaluation of the literature was done. We obtained prior papers from WHO publications, CDC publications, Google Scholar, Elsevier, PubMed, and EBSCOhost. The assessment examines the current status and future prospects of vaccine manufacturing in Africa, emphasizing obstacles, innovations, and possibilities. Results: Africa's vaccine manufacturing capacity is constrained by limited production infrastructure, a shortage of skilled personnel, and inadequate technical resources. These challenges are compounded by financial constraints, heavy reliance on donor support, and restricted access to technology transfer. In remote regions, regulatory fragmentation and weak cold chain infrastructure further hinder vaccine distribution. Promising innovations such as mRNA platforms, heat-stable formulations, and microarray patches offer potential breakthroughs, but progress in scaling up manufacturing remains slow despite international partnerships and funding support. To achieve vaccine self-sufficiency, Africa must strengthen its research ecosystem, build a skilled workforce, and expand domestic manufacturing capabilities. Conclusion: Africa's vaccine manufacturing capacity is at an important phase, requiring coordinated efforts to overcome long-standing barriers. Investment in local vaccine facilities, skilled personnel development, and strong regulatory framework are essential. Strengthening international partnerships while fostering local innovations will lead to self-reliance. Emphasis on One Health approaches can enhance disease surveillance and control. Adequate funding and political will are indispensable for sustained progress.

Indexed as

Africaproduction capabilitiespublic healthvaccine coveragevaccine manufacturing

Identifiers

PMID41773217
PMCPMC12949823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.